annoucements that keep rolling out

STI over the last couple of months has gathered a lot of interest. For a long time was close to receivership, however now has a new Director Peter Boonen

Note i have posted most of the recent announcements after an introduction to Peter Boonen taken from http://www.hotcopper.com.au/asx_announcements.asp?id=57909

Firstly, my name is Peter Boonen and I am the managing Director of Stirling Products Limited. I
was appointed to the Board on the 9th February this year along with my fellow directors, non
executive George Karantzias, and executive, CFO and joint company secretary, Gulshan Jugroo.
The 2008 year was a very difficult year for many companies, especially junior companies, and
Stirling Products was no exception. Your Company came very close to being placed into formal
administration following it being unsuccessful in raising funds at $0.003 a share late last year.
Since my involvement, we have successfully positioned the Company to be able to go forward,
not only in a fully funded situation, but also with an exciting pipeline of additional and
complementary products of which at least five or six have the real potential of attaining industry
recognised blockbuster status.
I have many people to thank for the tremendous effort in repositioning the Company within a
very short time frame of only four months. My co-directors, my team at Zodiac Capital Limited,
our team in Canada, our new partners, our new investors that have shown great support in a still
uncertain market place and especially to our many shareholders that today continue to hold, and
in many cases supplement their investment

SWINE FLU PREVENTION AND TREATMENT POTENTIAL
FOR IMMEDIATE RELEASE
16 April 2009
• Immunoxel Proven Effective in Flu Prevention and Treatment
• Immunoxel is a Major Seller in Ukraine Pharmacies During Flu Season
• Over Half a Million People in the Ukraine buy Immunoxel

http://www.hotcopper.com.au/asx_announcements.asp?id=49277

STIRLING PRODUCTS ENTERS INTO MAJOR JOINT VENTURE IN SOUTH
AFRICA AND AFRICA
FOR IMMEDIATE RELEASE
7 MAY 2009

http://www.hotcopper.com.au/asx_announcements.asp?id=52293

AIDS PATIENTS IN TRIAL RESPOND TO IMMUNOXEL
FOR IMMEDIATE RELEASE
14 May 2009
http://www.hotcopper.com.au/asx_announcements.asp?id=54465

STIRLING PRODUCTS ENTERS INTO MAJOR JOINT VENTURE IN SOUTH
AFRICA AND AFRICA
FOR IMMEDIATE RELEASE
7 MAY 2009
• Joint Venture entered into
• Dr Hinner Köster appointed as a Stirling Advisor

http://www.hotcopper.com.au/asx_announcements.asp?id=52293

IMMUNOXEL APPROVED IN SOUTH AFRICA
FOR IMMEDIATE RELEASE
26 May 2009
• Approval allows for Immunoxel sales as a TB and HIV treatment adjuvant

http://www.hotcopper.com.au/asx_announcements.asp?id=57021

INFLUENZA, TB AND AIDS PRODUCTS TO BE PRIORITISED
FOR IMMEDIATE RELEASE
2 June 2009
Australian healthcare company Stirling Products (ASX:STI) advise

http://www.hotcopper.com.au/asx_announcements.asp?id=59046

PROGRESS REPORT AND FIRST SALES
FOR IMMEDIATE RELEASE
4 June 2009
• First Product Sales
• Canadian Operations restructured
• Pulmovet Joint Venture mutually terminated

http://www.hotcopper.com.au/asx_announcements.asp?id=59697

DISTRIBUTION AND PRODUCT SALE AGREEMENT - MEXICO
FOR IMMEDIATE RELEASE
10 June 2009

http://www.hotcopper.com.au/asx_announcements.asp?id=60771

22 June 2009
Australian healthcare company Stirling Products (ASX:STI) advises that following the
establishment of a Multi-Level Marketing (MLM) test marketing initiative in Mongolia recently
growth has been rapid over the past few weeks as news of the effectiveness of the Company’s
phytopharmaceutical products spreads through word of mouth.
A total 377 agents have now been appointed and will be addressed at a meeting in Ulaan
Bataar, Mongolia this evening by the Company’s Managing Director, Mr Peter Boonen.
Gross sales are increasing rapidly, on a weekly basis, and last week achieved US$33,000 with
the main demand being for Cholonorm (reduction of LDL cholesterol), Diabetin (reduction of
blood sugar) and Immunoxel (Immune booster and flu prevention).
The MLM market strategy is now being planned to be expanded into Russia which has a far
greater population base and thereby opportunity than the Mongolian test market.
The Company further advises its first sale of ProVale into the US market through an initial
US$12,000 sale to a US animal feed manufacturer. Recent coverage on the development of
ProVale by the National Research Council of Canada can

http://www.hotcopper.com.au/asx_announcements.asp?id=63677